Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma

Table 2

Objective response rate according to clinical characteristics.

Clinical features	CR + PR (n)	SD + PD (n)	χ^2	value
Gender
Male	5	19	0.317	0.574
Female	4	23
Age
≥60 years	4	17	0.048	0.826
<60 years	5	25
ECOG
≥2	2	17	1.057	0.304
0–1	7	25
Subtype
Acral	3	13
Mucosal	3	14	0.025	0.987
Non-CSD/CSD	3	15
BRAF V600E
Mutant-type	2	9
Wild-type	4	16	0.175	0.916
Unknown	3	17
PD-1 blockade
Alone	4	34	5.201	0.023
Combination	5	8
PD-1 blockade agent
Nivolumab	5	25	0.048	0.826
Pembrolizumab	4	17
Liver metastasis
Yes	0	15	4.554	0.033
No	9	27
Treatment-naïve
Yes	7	23	1.621	0.203
No	2	19
LDH level
Normal	7	28	1.782	0.182
Elevated	2	14
ALB level
Normal	9	37	N/A	N/A
Lowered	0	5
CRP level
Normal	2	32	9.735	0.002
Elevated	7	10
NLR
≥2.3	6	16	2.741	0.140
<2.3	3	26
PLR
≥162.5	6	16	2.289	0.157
<165.5	3	26

CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; ECOG: Eastern Cooperative Oncology Group; CSD: chronic sun-damaged; LDH: lactate dehydrogenase; CRP: C-reactive protein; ALB: albumin. All values were two-tailed.